SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?


To: Brian Malloy who wrote (1141)1/8/1999 2:19:00 PM
From: Dan Spillane  Respond to of 1580
 
The "generics" discussion with respect to Celebrex:

techstocks.com




To: Brian Malloy who wrote (1141)1/11/1999 10:31:00 PM
From: Brian Malloy  Read Replies (2) | Respond to of 1580
 
Things continue to look good for Vioxx. Hopefully we will get the magic words that Vioxx does not increase the chance of PUD. I believe they stand a good chance. They could have rushed the product to market but they did appropriate clinical testing with sample sizes larger than required for approval and it will pay off big. Poor little analysts that think MRK has no pipeline. There will be a long line of them in the Pharmacy in 2001 when the Substance P based Anti-depressant hits the market as well.

FDA Grants Priority Review for Vioxx(TM), Merck's Investigational Medicine for Osteoarthritis and Pain
biz.yahoo.com